Moldova Authorizes 28 New Medicines for Pharmacy Distribution
The regulatory landscape for pharmaceuticals in Moldova shifts this August as the Medicines and Medical Devices Agency (AMDM) authorizes 28 new medications for domestic pharmacy distribution. According to official reporting from Radio Chișinău, the August authorization cycle encompasses 38 total pharmaceutical products, split between 28 first-time registrations and 10 repeat authorizations.
- AMDM authorized 38 total pharmaceutical preparations in August, featuring 28 first-time registrations.
- New approvals introduce specialized therapies including Sapropterin Dipharma for BH4 deficiency and Cytarabinum for acute leukemias.
Expanding Access to Orphan Drugs for Rare Metabolic Disorders
Among the newly authorized therapeutics is Sapropterin Dipharma, available in soluble tablet form with the International Nonproprietary Name (INN) Sapropterinum. The active pharmaceutical ingredient functions as a synthetic copy of tetrahydrobiopterin (BH4), a substance present in the human body. The medication is used in patients of all ages for the treatment of an inherited disease — BH4 deficiency, in which the body cannot produce a sufficient amount of this substance.
Targeting Hematologic Malignancies with Cytotoxic Agents
The August authorization registry also incorporates Cytarabinum (Citarabină) in injectable and perfusion solution formats. As a cytotoxic agent, cytarabine is used for the treatment of acute leukemias — blood cancer in which an excessive number of white blood cells is observed. The drug prevents the development of cancer cells, eventually leading to their destruction.
Supply Chain Stability and Regulatory Compliance
Disclaimer: The information provided in this article is for educational and scientific communication purposes only and does not constitute medical advice. Always consult with a qualified healthcare provider regarding any medical condition, diagnosis, or treatment plan.